ALKS

Wall Street expects a year-over-year decline in earnings on higher revenues when Alkermes (ALKS) reports results for the quarter ended September 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This drugmaker is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of -116.3%. Revenues are expected to be $465.92 million, up 18.2% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Alkermes, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +50.00%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Alkermes will beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Alkermes would post a loss of$0.04 per share when it actually produced break-even earnings, delivering a surprise of +100.00%. Over the last four quarters, the company has beaten consensus EPS estimates four times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Alkermes doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both regimens used split doses. The 50-participant Phase 1b trial included placebo, but those figures measure changes from patients' starting scores. Safety and tolerability were the primary objectives. For Alkermes plc (NASDAQ:ALKS), the results support further testing while leaving the size of any benefit over placebo unresolved. Read Also: Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? ALKS 7290 activates orexin 2 receptors, part of a brain signaling system involved in wakefulness and attention. Alkermes plc (NASDAQ:ALKS) is testing whether this approach can address ADHD alongside its broader work in sleep disorders. Success would expand the commercial possibilities of the orexin portfolio into another treatment setting. For Alkermes plc (NASDAQ:ALKS), an additional treatment mechanism could matter if it offers patients a useful balance of symptom control and tolerability. A different biological target creates room for differentiation, although the larger study must establish what patients actually gain. Alkermes plc (NASDAQ:ALKS) also has an established business behind its development effort. Second-quarter revenue totaled $496.0 million, while company-wide research and development expense was $112.9 million. A successful ADHD program could add another future product to that business and improve the return on its research investment. Take a look at: Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? The trial was not designed or powered to establish statistically significant differences between treatment groups. Alkermes plc (NASDAQ:ALKS) did not report a placebo-adjusted symptom benefit. Improvement from baseline can include effects unrelated to the drug, so the headline reductions cannot establish how much improvement treatment itself caused. The larger reduction at 50 mg is worth investigating, but it does not establish that the higher dose works better. For Alkermes plc (NASDAQ:ALKS), dose selection must balance efficacy with side effects. No serious treatment-emergent adverse events or treatment-group discontinuations were reported; common adverse events included insomnia, urinary symptoms, and dizziness. Two weeks of treatment cannot establish long-term safety or sustained symptom control. Alkermes plc (NASDAQ:ALKS) must also translate results from a short inpatient study into a treatment patients can use consistently in daily life. Even a positive efficacy result would leave questions about durability, dosing convenience, and positioning against existing therapies. Those factors will influence eventual adoption and pricing. The filings available so far reflect positions held before Alkermes plc (NASDAQ:ALKS) reported its early ADHD trial results. Insider Monkey's database showed 55 hedge funds holding Alkermes plc (NASDAQ:ALKS) at the end of 2Q2026, down from 56 funds three months earlier. Alkermes plc (NASDAQ:ALKS) has a credible reason to continue development. The enrolling Phase 2 trial targets approximately 312 participants and will compare symptom-score changes with placebo at four weeks, with results expected in 2027. The decisive evidence will be the size of that difference, consistency across doses, and tolerability. A clear benefit over placebo would strengthen the case for further investment in ADHD. Longer-term results would then need to support a treatment profile that physicians and patients find useful. While we acknowledge the potential of ALKS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Pan American Silver (PAAS) Updates its Reserve Base. How Much Growth Reflects Better Mines? and Lennar (LEN) Cuts Delivery Forecast. Can Construction Savings Offset Heavy Incentives? This article is originally published at Insider Monkey.

Alkermes plc (NASDAQ:ALKS) shares gained 6.5% on Monday after the company reported positive Phase 1b clinical trial results for ALKS 7290, an investigational treatment for adults with attention-deficit hyperactivity disorder (ADHD). The company said the findings demonstrated clinical proof of concept, with improvements in ADHD symptoms observed after 14 days of treatment. According to Alkermes, ALKS 7290 is the first orexin 2 receptor agonist to demonstrate clinically meaningful improvements in ADHD symptoms in adults. The drug was generally well tolerated across the doses evaluated in both healthy volunteers and adults with ADHD. The double-blind, placebo-controlled study enrolled 50 adults with ADHD. Participants received ALKS 7290 at total daily doses of either 20 mg or 50 mg, or a placebo, over a 14-day treatment period. The trial assessed safety and tolerability alongside exploratory measures of changes in ADHD symptoms from baseline. On the Adult ADHD Investigator Symptom Rating Scale, participants receiving ALKS 7290 demonstrated median symptom score reductions of 14.0 points at the 20 mg dose and 19.0 points at the 50 mg dose by day 14. The median baseline score was approximately 39 points. These results indicate improvements from baseline in both active-treatment groups. The reported figures do not, however, establish the magnitude of the treatment effect relative to placebo. ALKS 7290 also produced improvements on the Clinical Global Impression-Severity Scale, which assesses the overall severity of a patient’s condition. At day 14, median scores had declined by 1.0 point in the 20 mg group and 2.0 points in the 50 mg group. According to Alkermes, these changes corresponded to a reduction in symptom severity from markedly or moderately ill to mildly ill. The findings provide preliminary evidence supporting further investigation of the drug, although larger and longer-duration studies will be needed to establish its efficacy and safety. Alkermes reported no serious treatment-emergent adverse events during the study. Most adverse events were mild. The most frequently reported included insomnia, increased urinary frequency, dizziness, changes in sustained attention, urinary urgency and constipation. Two participants in the placebo group discontinued the study, while no participants receiving ALKS 7290 withdrew. The company said the drug was generally well tolerated at all doses tested. Alkermes is currently enrolling patients in a Phase 2 study of ALKS 7290 in adults with ADHD. Data from that trial are expected in 2027. The next stage of development will provide an opportunity to evaluate the drug’s efficacy and safety in a larger patient population and further investigate the findings from the Phase 1b programme. Alkermes stock price

— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults — — ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD — — Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Expected in 2027 — DUBLIN, September 21, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n=50). In the phase 1 study, ALKS 7290 was generally well tolerated at all doses tested in healthy volunteers and adults with ADHD. In adult participants with ADHD, ALKS 7290 demonstrated dose-dependent, clinically meaningful improvements on exploratory endpoints evaluating change from baseline on established clinical scales, the Adult ADHD Investigator Symptom Rating Scale (AISRS) and Clinical Global Impression-Severity Scale (CGI-S), at day 14 of treatment. These findings represent the first clinical evidence of the effects of an orexin receptor agonist in the treatment of ADHD and further support the dose range selected for the ongoing phase 2 study evaluating the efficacy and safety of ALKS 7290 in adults with ADHD. "ADHD is a common mental health condition that can have profound effects on multiple aspects of daily life, including academic achievement, career success, relationships and overall physical and emotional well-being. For many patients today, there remains a critical need for differentiated therapies that provide strong, well-tolerated efficacy," said Greg Mattingly, M.D., Founding Partner of St. Charles Psychiatric Associates, President at Midwest Research Group and Associate Clinical Professor in the Department of Psychiatry at the Washington University School of Medicine. "These data provide early evidence supporting the potential of the orexin pathway to influence the brain’s neural networks that are linked to ADHD and suggest that ALKS 7290 could represent a meaningful new therapeutic approach for patients." The phase 1b study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts. Following a two-week washout of existing ADHD medications, participants were randomized (4:1, active:placebo) within each cohort to receive ALKS 7290 (total daily dose of 20 mg (n=20) or 50 mg (n=20), administered in split doses) or placebo (n=10) for 14 days of inpatient treatment. In addition to safety, tolerability and PK and PD effects, the study evaluated change from baseline across a range of exploratory endpoints to begin to characterize the effects of ALKS 7290 on symptoms of ADHD. The study was not designed or powered to detect statistically significant differences between treatment groups. Topline results from the study include: Clinical Endpoints AISRS 1: ALKS 7290 demonstrated clinically meaningful2 improvements from baseline in ADHD symptoms as measured by the AISRS, a 54-point, clinician-administered, validated measure of ADHD symptom severity. At baseline, participants had a median AISRS total score of approximately 39, consistent with substantial ADHD symptom burden. Clinically meaningful improvements were observed as early as day 6, the first post-baseline AISRS assessment. At day 14, treatment with ALKS 7290 demonstrated median reductions from baseline in AISRS total scores of 14.0 points for the 20 mg dose and 19.0 points for the 50 mg dose. Clinically meaningful improvements were observed across AISRS Inattentive and Hyperactivity/Impulsivity subscales. CGI-S 3: ALKS 7290 demonstrated clinically meaningful2 improvements from baseline in overall ADHD disease severity as measured on the CGI-S scale. At baseline, participants had median CGI-S scores of 4.0 and 5.0 in the 20 mg and 50 mg dose groups, respectively. Clinically meaningful improvements were observed as early as day 6, the first post-baseline CGI-S assessment. At day 14, treatment with ALKS 7290 demonstrated median reductions from baseline in CGI-S scores of 1.0 for the 20 mg dose and 2.0 for the 50 mg dose, representing a shift in disease severity from markedly or moderately ill to mildly ill. CNS Biomarkers and Objective Cognitive Performance Tests The phase 1b study included multiple EEG-based biomarkers and performance-based cognitive tests designed to measure dose-related central activity and domains underlying ADHD symptoms. Findings from these assessments support our dosing decisions for phase 2 and showed treatment effects of ALKS 7290 across important cognitive domains, including processing speed, information processing, working memory and attention. Topline Safety ALKS 7290 was generally well tolerated across all doses tested in participants with ADHD. No serious treatment-emergent adverse events (TEAEs) were reported. Most TEAEs were mild in severity. The most common TEAEs4 were insomnia, pollakiuria, dizziness, change in sustained attention, micturition urgency, and constipation. There were no clinically significant findings observed in hepatic or renal parameters, vital signs or ECGs. Two participants in the placebo group discontinued the study; there were no discontinuations among participants receiving ALKS 7290. In healthy volunteers (n=88), single- and multiple-ascending doses of ALKS 7290 were evaluated for up to 10 days. ALKS 7290 was generally well tolerated across all doses tested and the maximum tolerated dose was not reached. ALKS 7290 was observed to be centrally active and to have a PK and PD profile that supports oral dosing with a wide therapeutic index. "Results from this phase 1 study of ALKS 7290 represent an important milestone in the advancement of our orexin portfolio and support our strategy to explore the potential of orexin biology beyond hypersomnolence disorders," said Craig Hopkinson, M.D. (MBChB), Chief Medical Officer and Executive Vice President of Research & Development at Alkermes. "This exploratory, first-in-patient study was designed to provide early insights into the potential of orexin 2 receptor agonism as a novel treatment for adults with ADHD, and we are excited to see the emerging clinical profile of ALKS 7290. The results begin to build the foundation of our understanding of ALKS 7290, and we look forward to further evaluating its safety and efficacy in our ongoing well-powered phase 2 study." A phase 2 study evaluating the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo in adults with ADHD is currently enrolling (NCT07755410). Following a two-week washout period of existing ADHD medications, participants will be randomized to receive one of three dosing regimens of ALKS 7290 or placebo. The study will evaluate the primary endpoint of change from baseline in AISRS total score at week four compared to placebo. The study is expected to enroll approximately 312 participants with ADHD. The first participant was dosed in September 2026. About the ALKS 7290 Phase 1 StudyThe phase 1 study for ALKS 7290 consisted of three parts: single-ascending dose and multiple-ascending dose evaluations in healthy volunteers (parts 1 and 2), and a phase 1b, proof-of-concept study in adults with attention-deficit hyperactivity disorder (ADHD) (part 3). In the healthy volunteer portion of the study, each cohort included eight participants, six of whom were randomized to receive ALKS 7290 and two of whom received placebo. In the multiple-ascending dose portion, participants received doses of ALKS 7290 for up to 10 days. The objectives of parts 1 and 2 of the study were to assess ALKS 7290’s safety, tolerability, pharmacokinetics and pharmacodynamics. The phase 1b proof-of-concept portion of the study (part 3) enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group study. Following a two-week washout period of existing ADHD medications, participants within each cohort were randomized in a 4:1 (active:placebo) ratio to receive split doses of ALKS 7290 (total daily dose of 20 mg or 50 mg) or matching placebo for 14 days of inpatient treatment. The primary objective was to evaluate the safety and tolerability of ALKS 7290. Changes from baseline on established clinical ADHD scales, including the ADHD Investigator Symptom Rating Scale (AISRS) and the Clinical Global Impression-Severity Scale (CGI-S), were assessed as an exploratory objective. The study was not designed or powered to detect statistically significant differences between treatment groups; findings disclosed are not in reference to any other study group. The study also included exploratory translational and neuropsychological performance measures to characterize the effects of treatment in a short duration study. About ALKS 7290ALKS 7290 is a novel, investigational, oral orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). Orexin, a neuropeptide produced in the lateral hypothalamus, plays a crucial role in regulating wakefulness, and engages multiple downstream pathways and neural circuits relevant to attention, cognition and mood.5 By targeting the orexin system, ALKS 7290 has the potential to address symptoms relevant to a broad range of disorders characterized by impairments in these domains. ALKS 7290 has been evaluated in a phase 1 study in healthy volunteers and adults with ADHD, and is currently being evaluated in a phase 2 study in adults with ADHD. About Alkermes plcAlkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com. Note Regarding Forward-Looking StatementsCertain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the potential therapeutic and commercial value of ALKS 7290, and the company’s expectations, including timelines, related to the ALKS 7290 development program. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: clinical study results for ALKS 7290 may not be predictive of results of future stages of ongoing clinical studies, future clinical studies or real-world results; clinical studies for ALKS 7290 may not be initiated or completed on expected timelines or at all; ALKS 7290 may be shown to be ineffective or unsafe; the FDA may not agree with the company’s regulatory strategies or components of its development program for ALKS 7290, including clinical trial designs, conduct and methodologies; potential changes in the cost, scope and duration of the ALKS 7290 development program; and those risks and uncertainties described under the heading "Risk Factors" in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2025 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260921142041/en/ Contacts Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377For Media: Gretchen Murphy, +1 781 609 6419

It has been about a month since the last earnings report for Alkermes (ALKS). Shares have added about 1.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Alkermes due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Alkermes reported break-even earnings for the second quarter of 2026 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company had recorded earnings of 52 cents per share in the year-ago quarter. During the second quarter, the company recorded a change in the fair value of contingent consideration of $26.4 million related to the Avadel acquisition contingent value right (CVR) milestone. Alkermes reported total revenues of $496 million for the second quarter, up almost 27% from the year-ago quarter, driven by higher product sales. The top line beat the Zacks Consensus Estimate of $454 million. Alkermes derives revenues from the net sales of its proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia), Lybalvi (schizophrenia and bipolar I disorder) and the newly acquired sleep disorder drug, Lumryz. The metric also includes manufacturing and/or royalty revenues on net sales of products commercialized by partners. Sales of the proprietary products portfolio grew 34% year over year to $411.7 million during the second quarter, driven by solid demand across the commercial portfolio. Sales of proprietary products were above management’s guided range of $385-$405 million. Vivitrol sales increased 2.3% year over year to $124.5 million in the reported quarter. The metric beat the Zacks Consensus Estimate of $117 million. Aristada sales decreased 4.5% year over year to $96.7 million. The figure, however, beat the Zacks Consensus Estimate of $95 million. Lybalvi generated sales of $94 million, up 11.5% year over year in the reported quarter, due to increased total prescriptions. Its sales, however, missed the Zacks Consensus Estimate of $98 million. Lybalvi’s total prescriptions grew 18% year over year in the quarter. Newly acquired sleep disorder drug Lumryz recorded revenues worth $96.6 million in the second quarter. The metric beat the Zacks Consensus Estimate of $89 million. Total manufacturing and royalty revenues increased 1.1% year over year to $84.3 million. Manufacturing and royalty revenues from Biogen’s multiple sclerosis drug, Vumerity, were $30.6 million. Royalty revenues from Xeplion and certain Invega products were $27.5 million in the second quarter. Research and development expenses totaled $112.9 million, up around 45.8% year over year. Selling, general and administrative expenses totaled $217.6 million, up around 27.4% year over year. As of June 30, 2026, Alkermes had cash and cash equivalents of $691.6 million compared with $538.2 million as of March 31, 2026. Alkermes reiterated its full-year 2026 guidance. The company expects total revenues in the band of $1.73-$1.84 billion for 2026, unchanged from the previous expectation. Net sales from proprietary products are expected in the range of $390-$410 million in the third quarter. Net sales of Vivitrol are expected to be in the range of $460-$480 million, while Aristada sales are anticipated in the range of $365-$385 million. Lybalvi’s net sales are expected in the $380-$400 million range. Net sales from Lumryz are expected to be in the range of $315-$335 million in 2026. Research and development expenses are anticipated in the range of $445-$485 million. Selling, general and administrative expenses are projected in the range of $890-$930 million. The company expects adjusted EBITDA to be in the range of $370-$410 million. In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -920% due to these changes. Currently, Alkermes has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Alkermes has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alkermes (NasdaqGS:ALKS) shares were in focus after the company reported its second quarter 2026 results on July 28, highlighting higher revenue alongside a significantly lower quarterly net income figure. See our latest analysis for Alkermes. Despite the weaker quarterly net income, Alkermes shares trade at US$48.99 after a recent pullback, with the 7 day share price return down 7.37% and the 30 day share price return down 5.28%. However, the 90 day share price return of 46.76% and 1 year total shareholder return of 84.52% point to strong longer term momentum as investors weigh the latest earnings, past buybacks and the new shelf registration. If Alkermes has you thinking about where growth and risk might sit next in healthcare, it could be worth scanning 41 healthcare AI stocks For Alkermes, the share price pullback comes right after strong recent returns and a quarter where revenue and earnings moved in very different directions. Is this latest swing mainly about sentiment, or about what the business is now worth? The most followed narrative pegs Alkermes' fair value at $47.69, only slightly below the current $48.99 share price, so expectations and price sit very close. Read the complete narrative. Want to understand why this narrative still supports a premium valuation multiple? The story leans heavily on compounded revenue growth, widening margins, and a richer earnings base several years out. Curious which specific growth path and profitability mix this view depends on, and how ambitious those assumptions really are? Result: Fair Value of $47.69 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Alkermes still faces clear risks if orexin trial outcomes disappoint or regulatory timelines slip, and if product concentration around Vivitrol, Aristada and Lybalvi bites harder. Find out about the key risks to this Alkermes narrative. While the most popular narrative on Alkermes points to a fair value of $47.69 and calls the stock slightly overvalued, the SWS DCF model presents a very different picture. It estimates fair value at $99.55, which is about 51% above the current $48.99 share price and frames Alkermes as undervalued. Which set of assumptions do you trust more? Look into how the SWS DCF model arrives at its fair value. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Alkermes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. With Alkermes carrying both clear risks and meaningful potential rewards, the key question is what matters most to you right now and how quickly you want to firm up your own view by reviewing the 2 key rewards and 3 important warning signs If Alkermes sharpened your focus on opportunities, do not stop here. Use the Simply Wall St Screener to quickly spot fresh ideas before the crowd catches on. Chase value opportunities that combine quality and attractive pricing with the 55 high quality undervalued stocks Prioritize resilience and peace of mind by scanning 81 resilient stocks with low risk scores Unearth lesser known businesses with strong fundamentals through the screener containing 19 high quality undiscovered gems This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ALKS. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies. The commercial strategy for LYBALVI shifted toward a long-term access model, successfully securing formulary placement with three of the largest Part D plans to cover over 80% of insured lives. VIVITROL's durability is attributed to high barriers to entry, specifically the specialized sterile manufacturing and formulation expertise required for microsphere production. The integration of Avadel and the LUMRYZ brand was described as exceeding expectations, with management noting that the team and culture have integrated seamlessly into Alkermes. Strategic positioning in sleep medicine now encompasses both oxybate and orexin mechanisms, which management believes uniquely positions the company to address the full spectrum of patient needs. Phase 3 narcolepsy program for alixorexton remains on track for expected completion in 2027., with a focus on establishing a best-in-class clinical profile. Management expects initial Phase 1b clinical data for ALKS 7290 in ADHD by the end of the third quarter of 2026, marking the first clinical evaluation of an orexin agonist in this population. The company plans to submit an sNDA for LUMRYZ in idiopathic hypersomnia by year-end 2026, targeting a potential launch as early as March 2028. Future R&D investment will be managed through a 'reinvestment' framework, where spending on new orexin indications will scale as the primary narcolepsy Phase 3 programs wind down. Management anticipates that Takeda's expected market entry will establish a 'price corridor' for the orexin class, which Alkermes will use to inform its own pricing strategy. The company terminated its authorized generic agreement for VIVITROL with Amneal, confirming no AG will enter the market in 2027. A $26.4 million change in the fair value of contingent consideration was recorded, reflecting an increased likelihood of achieving milestones following positive LUMRYZ Phase 3 results. Gross-to-net adjustments for LYBALVI are expected to expand in the second half of 2026 due to the strategic investment in broader Part D insurance coverage. Management flagged that manufacturing revenue for RISPERDAL CONSTA has been largely realized for the year, with no meaningful contributions expected for the remainder of 2026. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management stated that adult data is highly translatable to pediatric populations through bridging PK studies, which will be addressed after dose-ranging is established in adults. The current Phase 1b study is primarily for safety and translation, utilizing EEG and behavioral markers to assess target engagement. The company is evaluating several established fatigue scales (MFIS, PFS-16) to align with the FDA on a primary tool for the regulatory path. The Phase 2a study for ALKS 4510 is designed to identify the signal necessary to define later-stage clinical study designs. Management noted significant physician and patient interest in using orexins to drive daytime wakefulness alongside oxybates for nighttime sleep consolidation. Alkermes plans to generate data on combination use to support clinicians and payers, though not necessarily for initial registrational purposes. CEO Richard Pops noted that while these programs could impact companies with foreign sales, Alkermes is not affected as it does not sell drugs at lower prices outside the U.S. He highlighted that such policies are particularly challenging for mid-sized companies that lack a large portfolio to offset pricing pressures.

Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this drugmaker would post a loss of $0.57 per share when it actually produced a loss of $0.4, delivering a surprise of +29.82%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Alkermes, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $496.01 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 9.26%. This compares to year-ago revenues of $390.66 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Alkermes shares have added about 88.5% since the beginning of the year versus the S&P 500's gain of 8.3%. While Alkermes has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Alkermes was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.01 on $472.48 million in revenues for the coming quarter and -$0.42 on $1.81 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. ADC Therapeutics SA (ADCT), another stock in the same industry, has yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +62%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. ADC Therapeutics SA's revenues are expected to be $20.15 million, up 7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

For the quarter ended June 2026, Alkermes (ALKS) reported revenue of $496.01 million, up 27% over the same period last year. EPS came in at $0, compared to $0.52 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $453.98 million, representing a surprise of +9.26%. The company delivered an EPS surprise of +100%, with the consensus EPS estimate being -$0.04. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacturing and Royalty revenues: $84.29 million compared to the $58.24 million average estimate based on four analysts. The reported number represents a change of +1% year over year. Revenues- Product sales, net: $411.72 million compared to the $396.31 million average estimate based on four analysts. The reported number represents a change of +34% year over year. Revenues- Proprietary Sales- VIVITROL: $124.5 million versus $117.17 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change. Revenues- Proprietary Sales- LYBALVI: $94 million versus $97.68 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11.5% change. Revenues- Proprietary Sales- ARISTADA: $96.7 million compared to the $94.97 million average estimate based on two analysts. The reported number represents a change of -4.5% year over year. Revenues- Proprietary Sales- LUMRYZ: $96.6 million versus the two-analyst average estimate of $88.88 million. View all Key Company Metrics for Alkermes here>>> Shares of Alkermes have returned +0.4% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research